Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS

Abstract

The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.

1 - 22 . (canceled) 
     
     
         23 . A polypeptide comprising an immunoglobulin Fc domain and a heterologous polypeptide, wherein the heterologous polypeptide is fused to the N-terminus or the C-terminus of the Fc domain by a polypeptide linker, wherein the polypeptide linker comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 55-62, 66-70, 86, 87, 89, 94, and 95. 
     
     
         24 . The polypeptide of  claim 23 , wherein the heterologous polypeptide is fused to the C-terminus of the Fc domain. 
     
     
         25 . The polypeptide of  claim 23 , wherein the heterologous polypeptide is fused to the N-terminus of the Fc domain. 
     
     
         26 . The polypeptide of  claim 23 , wherein the heterologous polypeptide comprises a tenth fibronectin type III ( 10 Fn3) domain. 
     
     
         27 . The polypeptide of  claim 23 , wherein the immunoglobulin Fc domain comprises a hinge or a portion thereof. 
     
     
         28 . The polypeptide of  claim 23 , wherein the immunoglobulin Fc domain is derived from IgG, IgM, IgD, IgE, or lgA. 
     
     
         29 . The polypeptide of  claim 28 , wherein the immunoglobulin Fc domain is derived from IgG. 
     
     
         30 . The polypeptide of  claim 29 , wherein the immunoglobulin Fc domain is derived from IgG1. 
     
     
         31 . The polypeptide of  claim 23 , wherein the polypeptide linker consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 55-62, 66-70, 86, 87, 89, 94, and 95. 
     
     
         32 . A composition comprising the polypeptide of  claim 23  and a carrier. 
     
     
         33 . A nucleic acid encoding the polypeptide of  claim 23 . 
     
     
         34 . A vector comprising the nucleic acid of  claim 33 . 
     
     
         35 . A host cell comprising the vector of  claim 34 . 
     
     
         36 . A method of detecting a target molecule in a sample, comprising:
 (a) contacting the sample with the polypeptide of  claim 23 , wherein said contacting is carried out under conditions that allow the polypeptide to form a complex with the target molecule; and   (b) detecting the complex.   
     
     
         37 . A method of treating a disease or disorder comprising administering the polypeptide of  claim 23  to a subject in need thereof.